RxDoctor Payments Data

Sandra Weber, MD

Endocrinology, Diabetes & Metabolism · Greenville, SCNPI 1821039041

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations.

$4,810in general payments, 2019–2025

Across 215 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$519
  • Insulet Corporation$481
  • Medtronic$387
  • Abbott$379
  • AbbVie$320
  • Lilly USA, LLC$282
  • plus $2K from 27 others
$182,532in research payments, 2019–2025

Across 375 payments — averaging $486.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$183K

What the payments were for

  • Food & beverage$4,68697%
  • Education$651%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,810 in reported general payments places this provider in the 60th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina

Medicare billing

Part B allowed, 2024
$139,852
Medicare patients
438
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide186$282,210
MounjaroTirzepatide146$194,125
TrulicityDulaglutide110$172,969
JardianceEmpagliflozin109$146,830
RybelsusSemaglutide57$81,767
Repatha SureclickEvolocumab71$81,033
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/763$79,856
FarxigaDapagliflozin Propanediol69$77,933
GlumetzaMetformin Hcl12$73,322
Humulin R U-500Insulin Regular, Human25$65,872
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres11$50,327
Tresiba Flextouch U-100Insulin Degludec59$46,634
Tresiba Flextouch U-200Insulin Degludec40$45,744
Praluent PenAlirocumab27$35,973
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$35,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$519$429,470343 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi$282$389,536330 claims
Boehringer IngelheimJardiance$221$146,830109 claims
NovartisSandostatin Lar Depot$69$50,32711 claims
AbbVieSynthroid$320$28,204320 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$51$12,6091,048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

Other endocrinology, diabetes & metabolism in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →